Characteristics and outcomes of patients treated with sotrovimab to prevent progression to severe COVID-19 in Belgium

Background

Coronavirus disease 2019 (COVID-19) is caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); the rapid global spread of SARS-CoV-2 resulted in the declaration of a pandemic by the World Health Organization in March 2020 [1]. Globally, as of September 2023, there have been over 770 million confirmed cases of COVID-19, including nearly 7 million deaths [2]. In Belgium, almost 158,000 hospitalizations and 34,000 deaths have been attributed to COVID-19 during the same period [2, 3].

Older individuals or those with immunosuppression, cancer, obesity, diabetes, or chronic kidney, lung, liver or cardiovascular disease are known to be at higher risk of developing severe COVID-19, which may result in hospitalization or death [4–6].

Sotrovimab is a dual-action, engineered human immunoglobulin G1κ monoclonal antibody (mAb) derived from the parental mAb S309, a potent neutralising mAb directed against the spike protein of SARS-CoV-2 [7–10]. Sotrovimab (administered as a single 500 mg intravenous dose) was shown in COMET-ICE, a randomized clinical trial, to significantly reduce the risk of all-cause >24-hour hospitalization or death compared with placebo in high-risk patients with COVID-19 [11].

As a result of positive findings from COMET-ICE, sotrovimab received marketing authorization from the European Medicines Agency (EMA) in December 2021 for use in adults and adolescents (aged ≥12 years and weighing ≥40 kg) with COVID-19 who do not require oxygen supplementation and are at increased risk of progressing to severe COVID-19 [12]. In Belgium, use of sotrovimab began prior to EMA approval as a result of a procurement framework contract issued by the European Commission in July 2021 that enabled participating European Union member states, including Belgium, to purchase sotrovimab prior to its marketing authorization [13, 14]. At the time of the study, mAbs (including sotrovimab) were recommended for the treatment of mild-to-moderate COVID-19 among patients in Belgium at high risk of complications, following authorization by a multidisciplinary team including at least one infectious disease physician and one immunologist [15]. Due to limited supplies of mAbs, immunocompromised patients were considered the highest priority for mAb treatment [15].

Sotrovimab has been granted marketing authorization in the European Union, Norway, Iceland [16], Australia (conditional) [17], United Kingdom (conditional) [18], Saudi Arabia (conditional) [19] and Switzerland (conditional) [19]. In Japan, a Special Approval for Emergency designation has been granted [20]. Since the approval of sotrovimab, waves of new SARS-CoV-2 variants of concern have emerged, including the Delta variant and the Omicron BA.1, BA.2 and BA.5 subvariants; the latter became dominant in Belgium in June 2022 [21–23]. In vitro neutralization studies have demonstrated a moderate fold shift in activity of sotrovimab against Omicron BA.2 relative to wild-type SARS-CoV-2 (16-fold change in EC₅₀ relative to wild-type) [24]. A similar reduction in activity was reported for sotrovimab against BA.5 (22.6-fold change in EC₅₀ relative to wild-type) [24]. Consequently, on 28 April 2022, the Federal Agency for Medicines and Health Products regulatory body in Belgium took the decision to no longer recommend the use of sotrovimab [25], although use continued among very-high-risk and/or immunocompromised patients.

In the absence of a clinical trial conducted during the Omicron predominance period, it remains uncertain how in vitro antibody neutralization activity correlates with clinical effectiveness, especially for dual-action antibodies like sotrovimab that have potent effector function, including antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis [10, 26, 27]. Real-world studies are an important source of data with which to assess clinical outcomes in patients treated with sotrovimab within the evolving variant landscape.

Here, we describe the real-world use of, and outcomes from, sotrovimab treatment for the management of patients with COVID-19 at high-risk of developing severe disease between 1 November 2021 and 2 August 2022 in Belgium, when the Delta variant and Omicron BA.1, BA.2 and BA.5 subvariants were predominant.

Methods

Study outcomes

Patient demographics and clinical characteristics were collected based on the presence of selected International Classification of Disease version 10 (ICD-10) and ATC codes (Tables S1–S3) during any hospital visit that occurred in the 12 months prior to the index date.

These included age, sex, and comorbidities and risk factors that may predispose patients to severe COVID-19 outcomes, as follows: immunocompromised status (human immunodeficiency virus infection/acquired immunodeficiency syndrome, treatment for solid tumours, haematological malignancy, solid organ or haematopoietic stem cell transplantation, primary immune deficiency, receiving immunosuppressive drugs [see Table S1], sickle-cell anaemia, major thalassaemia, asplenia); other risk factors or comorbidities of interest (age ≥65 years old, obesity, type 1 or type 2 diabetes mellitus, chronic lung disease including asthma and cystic fibrosis, cardiovascular disease including uncontrolled hypertension, chronic kidney disease [CKD; estimated glomerular filtration rate <30 ml/min] including treatment via haemodialysis, chronic liver disease [Child–Pugh B or C], chronic neurological disease). These comorbidities and risk factors for severe COVID-19 aligned with those reported by the Scientific Institute for Public Health of the Federal Belgian State (Sciensano) and the US Centers for Disease Control and Prevention [5, 6].

The clinical outcomes of this study included the number and proportion of all-cause and COVID-19-related hospitalizations and all-cause deaths during the acute period (29 days after the index date). COVID-19-related hospitalizations were defined as having the following ICD-10 codes registered as the verified admission diagnosis: B34.2, B97.2 or U07.1 (Table S2). In a post hoc analysis, cause of death data were collected for patients at Ghent University Hospital and the proportion of COVID-19-related deaths was determined; only all-cause deaths are reported for the other centres.

The number and proportion of all-cause and COVID-19-related hospitalizations and all-cause deaths among sotrovimab-treated patients were reported for the overall population and stratified by week and month, as well by the period of SARS-CoV-2 variant predominance in Belgium [28], as follows: Delta predominance period, 4 November 2021– 23 December 2021; Delta/BA.1 codominance period, 24 December 2021–1 January 2022; BA.1 predominance period, 2 January 2022–9 February 2022; BA.1/BA.2 codominance period, 10 February 2022–7 March 2022; BA.2/BA.5 codominance period, 8 March 2022–2 August 2022 (Fig. 1). The study design did not enable collection of polymerase chain reaction results in order to identify the SARS-CoV-2 variant strains that patients were infected with. Rather, to map the 29-day outcomes with the circulating variants, we used a proxy based on the most prevalent strains circulating in Belgium per week, as provided by Sciensano [28].

• Download figure
• Open in new tab

Fig. 1

Proportion of SARS-CoV-2 variants over time in Belgium [28]. SARS-CoV-2=severe acute respiratory syndrome coronavirus 2

In addition, the length of stay (defined as number of hospitalization days), time to hospitalization after the index date, number and proportion of patients admitted to intensive care, and the number and proportion of patients receiving non-invasive or mechanical ventilation during all-cause or COVID-19-related hospitalization were captured during the acute period.

In an exploratory analysis, all-cause and COVID-19-related new hospitalizations and all-cause deaths reported during the post-acute period, defined as the period between Day 30 and Day 90 after the index date, were assessed. Data for the exploratory analysis could only be collected for patients identified on or before 1 June 2022 to allow time for Day 30–90 follow-up to be completed before the end of the study period (31 August 2022).

Results

Discussion

This single-arm, retrospective study describes the real-world clinical outcomes of patients with COVID-19 who received sotrovimab treatment across nine hospitals in Belgium between 1 November 2021 and 31 August 2022. Over two-thirds (67.7%) of the patients in this study had at least one immunocompromising condition, with over one-third of patients (36.9%) receiving chemotherapy for an underlying malignancy. Other commonly reported risk factors for progression to severe COVID-19 were age ≥65 years old, cardiovascular diseases (including uncontrolled hypertension), diabetes and CKD. Comparatively, national hospital surveillance, conducted by Sciensano, identified hypertension, cardiovascular disease and diabetes as the top three most frequently reported comorbidities among patients with COVID-19 hospitalized in Belgium over the course of the pandemic [29].

During this study, 12.9% of patients (n = 82/634) treated with sotrovimab were hospitalized or died due to any cause during the 29-day acute period. This rate is relatively high compared with rates reported in other retrospective or observational studies (all-cause hospitalization and/or mortality ranged from 2.1% to 2.7% during the BA.1 predominance period and from 1.7% to 2.0% during the BA.2 predominance period in a recent systematic literature review reporting on the real-world effectiveness of sotrovimab [30]), but this may be potentially explained by several observations. Firstly, high proportions of all-cause and COVID-19-related hospitalizations were mainly observed among sotrovimab-treated patients during the Delta predominance period (4 November to 23 December 2021) in Belgium.

These observations align with nationally reported records of high rates of COVID-19-related hospitalization (12,588 admissions) and deaths (1935) during the Delta predominance period [3, 31] and may reflect the higher disease severity, higher prevalence and more rigorous public health measures associated with the Delta variant relative to subsequent Omicron variants, as well as lower immunity within the population [32, 33]. Additionally, the present study period spanned four SARS-CoV-2 variants (Delta, BA.1, BA.2 and BA.5) compared with one to two variants (primarily BA.1 or BA.2) in other studies [34–36]. Furthermore, the current study had a relatively high proportion of patients with at least one immunocompromising condition (67.7%) compared with other studies [34, 35, 37, 38]. This higher proportion of high-risk patients, necessitating regular inpatient treatment for their underlying conditions, may explain the relatively higher rate of all-cause hospitalization or mortality observed in this current study compared with other real-world studies [30, 34, 35, 39].

In a recent Danish cohort study, 83% of 2933 sotrovimab-treated patients belonged to very-high-risk groups that included haematological malignancy, solid organ transplantation, and treatment with anti-CD20 for non-malignant haematological diseases within the previous year. Within 90 days of sotrovimab treatment (696 person-years), 30.2% of patients were hospitalized and 5.3% had died due to any cause. The highest prognostic factor was haematological malignancy, followed by age ≥65 years [40]. Comparatively, in our study, 68% of patients had at least one immunocompromising condition. A quarter (25.4%) of patients had a haematological malignancy and 36.6% were aged ≥65 years; our 30–90-day results show that 13.8% of patients had a new hospitalization event (any cause), and 1.1% died due to any cause. Similar to our findings, the Danish study found a higher proportion of hospitality and death associated with the Delta variant, but no major differences in these outcomes were observed between the Omicron BA.1 and BA.2 variants [40].

In our study population, the proportion of sotrovimab-treated patients experiencing COVID-19-related hospitalization was highest during the Delta predominance and Delta/BA.1 codominance (both 6.3%) periods. During the BA.1 predominance, BA.1/BA.2 codominance and BA.2/BA.5 codominance periods, COVID-19-related hospitalizations were consistently low (all ≤2.7%). The median duration of hospitalization in our study (10.0 days) was higher than the national reported figure for Belgium, of 2 days, during the Omicron predominance period [41]; however, the median duration of ICU stays (4.0 days) was the same as the national median duration reported for Belgium [41]. It should be noted that the number of patients admitted to an ICU was low (n = 3), which limits interpretation.

This study has several potential limitations that should be considered. Firstly, this descriptive, single-arm study did not include a comparator arm, such as patients with similar risk profiles who did not receive sotrovimab after SARS-CoV-2 infection. We were not able to derive a control group due to a lack of similarly high-risk patients who had not received sotrovimab treatment and because patients who did not receive sotrovimab and were not hospitalized were not accounted for in the data used in this study. As a result, it is difficult to infer an association between sotrovimab treatment and clinical outcomes from these data alone. Due to the retrospective, observational study design, variables such as vaccination status and disease severity at enrolment could not be extracted, as these were not structurally reported and standardized in all hospitals. However, vaccination rates in Belgium had reached 73% by the start of this study [42] (and were presumably higher in high-risk groups similar to this study population). Furthermore, one might assume a high vaccination uptake in this population, with patients having received regular follow-up at their treating hospital and being eligible for early treatment with mAbs. Patients who received sotrovimab as an inpatient were excluded from the study, with the exception of patients who were discharged the day after sotrovimab administration. This comprised a large proportion of the total number of patients identified (48.5% [n = 598/1232], potentially inducing selection bias in the analyses and limiting the generalizability of the findings. In addition, patients who received sotrovimab in one of the selected hospitals but were later admitted to a different hospital where they progressed to severe disease may not have been captured in our study given its retrospective nature. However, as sotrovimab is expected to be primarily used in patients at risk of progressing to severe outcomes, such as those who are immunocompromised, these patients were likely associated with a reference hospital given their need for frequent medical care; therefore, missing data for clinical outcomes were likely to be low. Similarly, data on the uptake of immunosuppressant drugs and diagnosis of comorbidities were only extractable for patients who were treated or diagnosed in the same hospital where they received their sotrovimab treatment. Information on drugs received in another hospital or prescribed in primary care were not available. Therefore, the number of patients who were at high risk of developing severe COVID-19 disease may have been underestimated. Lastly, as variant sequencing was not routinely undertaken, the specific SARS-CoV-2 variant with which patients were infected could not be determined. Instead, an ecological design was proposed that used the periods of Delta, BA.1, BA.2 and BA.5 subvariant predominance and codominance as a proxy for the infecting variant. National genomic surveillance data were used to stratify the study periods into circulating variant predominance periods [28].

Conclusions

This observational study demonstrated consistently low rates of COVID-19-related hospitalizations and all-cause deaths in sotrovimab-treated patients during the Omicron subvariant predominance periods in Belgium, despite the reported decrease in in vitro neutralization activity of sotrovimab against BA.2 and BA.5, and over two-thirds of the study population being immunocompromised. Comparative effectiveness studies are warranted to confirm the effectiveness of sotrovimab in highly immunocompromised patients with COVID-19.

List of abbreviations

ATC

Anatomical Therapeutic Chemical

CKD

chronic kidney disease

COVID-19

coronavirus disease 2019

EMA

European Medicines Agency

ICD-10

International Classification of Disease version 10

ICU

intensive care unit

IQR

interquartile range

mAb

monoclonal antibody

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

SD

standard deviation

Declarations

Additional files

Additional file 1 (PDF) - Supplementary Appendix, containing ATC and ICD-10 codes used in this study, and all-cause and COVID-19-related outcomes by study month